Also, we discuss in detail the potential contribution of distinct inhibitors of pro-inflammatory signaling pathways derived from the natural sources that can be utilized both for the prevention and the treatment of MM.doi:10.1007/s11101-013-9287-3...
Treatment of multiple myeloma with recombinant α-interferon Thirty-two patients with multiple myeloma were treated with recombinant alpha-interferon clone A (rIFN alpha A) daily by intramuscular injection with an initial dose of 12 X 10(6) U/m2. Of 27 patients evaluable for response, tumor re...
Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. In order to assess the role of alpha-interferon or as maintenance therapy for , 172 consecutive, previously untreated patients with disease of low or inter... R Alexanian,D Weber,M Dimopoulos,......
whereby proliferation of malignant plasma cells is not checked by the immune system," said Shah. "Long-term remissions in some patients after stem cell transplants from donors have been observed, but treatment-related toxicity limits the widespread use of this therapy." ...
Novel therapies capable of targeting drug resistant clonogenic MM cells are required for more effective treatment of multiple myeloma. This study investigates the cytotoxicity of natural killer cell lines against bulk and clonogenic multiple myeloma and evaluates the tumor burden after NK cell therapy in...
Lice Treatment Liver Disease Loss of Hair Low Blood Pressure Low Blood Sugar Low Immunity Lyme Disease Malaria Mastitis Measles Menopausal Disorders Menstrual Cramps Menstrual Problems Migraine Moles Mononucleosis Morning Sickness Mumps Nasal Congestion ...
Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma Data indicate reversal of immune dysfunction with active treatment; however, the precise contribution of specific immune effector and immune suppressor com... Bhutani, Manisha...
stem/progenitor cells, impairing differentiation and causing dysregulated proliferation, resulting in autonomous and disordered proliferation of immature blasts (leukemic cells). Intensive chemotherapy is the primary treatment for patients with AML, with some undergoing HSCT based on risk stratification [1]....
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. By directly activating natural killer cells and by antibody-dependent cell-mediated cytotoxicity, elotuzumab exhibits a dual mechanism of action leading to ... Weisel,Katja. - 《Oncotargets & Therapy》 被引量: 5...
Several of these natural products have been developed into anticancer drug candidates, and one proteasome inhibitor has already been approved for the treatment of multiple myeloma. Despite the wealth of information available about naturally occurring proteasome inhibitors and related compounds, it is clear...